HIBSAGO
Nov 06, 2026
GSK/Ionis’ HIBSAGO: How the First FDA-Approved Antisense Drug for Chronic Hepatitis B Could Change the Treatment Arena
Summary On October 20, 2026, the FDA approved HIBSAGO (bepirovirsen), the first antisense oligonucleotide for chronic hepatitis B, from Ionis and GSK. In the B-Well trials, 19% reached functional cure at week 72 versus 0% on placebo, and 26% when baseline HBsAg was 1,000 IU/mL or less. About 16 developers...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
